XCancer

FBnTP Imaging of Breast Cancer

Description:

Our preclinical studies suggest the capacity of the positron emission tomography imaging agent 18F-fluorobenzyl triphenyl phosphonium (FBnTP) to detects early-stage small breast tumors (e.g., DCIS), and differentiates benign from malignant masses with better accuracy than that obtained by existing breast imaging tools.

Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase:

Phase 1

Contacts:

Martin Pomper, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT02204462 - Click here to see study on

ClinicalTrials.gov

FBnTP

Isotope(s):
Target(s):
  • Mitochondria-Targeting Moieties
Ligand Class: Small Molecules
Inclusion
  • Age \> 25 Ability and willingness to sign informed consent prior to any study procedure.
  • * Female patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e., index cancer)
  • Ability to undergo up to 90 minutes of PEM imaging.
  • Positive indication of disease on mammogram or MRI scan.
  • Candidate for breast cancer surgery on the basis of recommendation of a breast cancer surgeon.
Exclusion
  • Inability to tolerate venous access.
  • Past or present history of active substance abuse (drug or alcohol).
  • * Any active or chronic illness that, in the opinion of the investigators, would make the study unsafe or limit compliance with study procedures.
  • Pregnant females are excluded from this study. All females of child-bearing potential will undergo a serum pregnancy test within 48 hours prior to FBnTP administration.